Barclays Maintains an 'Underweight' on Omnicare (OCR); Updating Estimates and 1Q11 Review

Barclays maintains an 'Underweight' on Omnicare (NYSE: OCR), PT $32.

Barclays analyst says, "We are making some modest adjustments to our estimates for OCR following their March quarter results. We are lowering our 2011 EPS estimate to $2.09 (down from $2.10) and lowering 2012 to $2.35 (down from $2.38). In addition, we are lowering our estimate for 2Q11 to $0.45 and note that the company's earnings are expected to be back-end loaded in 2011."

"We continue to believe the Omnicare story is more about 2012, with the market paying little attention to the lack of growth in 2011..."

For more ratings news on Omnicare click here and for the rating history of Omnicare click here.

Shares of Omnicare closed at $31.65 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Morgan Stanley course-corrects their semiconductor equipment outlook on demand
• Vireo Growth completes acquisition of C21 Investments